| Clemson University, BS |
John Taylor is responsible for corporate and business development at Synageva. John has over 15 years of business and deal experience in business development and corporate leadership roles. John joined Synageva in September 2009 from Javelin Pharmaceuticals (acquired by Hospira) where he was Vice President, Business Development and responsible for the company’s business development and licensing functions and leading the global partnering efforts for Javelin’s portfolio of products. These efforts resulted in the successful out-licensing of Javelin’s lead product, Dyloject, in Europe, and the divestiture of Javelin’s UK subsidiary. Prior to Javelin, John was a senior business development executive at Eurand, Inc., a GI specialty pharmaceutical and drug delivery company (acquired by Axcan Pharma). During his tenure at Eurand, John closed a number of major transactions. John has also held positions in business development, licensing, marketing and sales with Sarnoff Corporation, Amersham Pharmacia Biotech, and BioWhittaker. He received his BS from Clemson University and his Masters of Technology Management from the Wharton School of Business/ University of Pennsylvania.
